Trial Profile
A PHASE II TRIAL OF ERLOTINIB AND AT-101 IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EGFR ACTIVATING MUTATIONS.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs AT 101 (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Jun 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 24 May 2010 Actual patient number (6) added as reported by ClinicalTrials.gov.
- 24 May 2010 Actual end date (1 May 2010) added as reported by ClinicalTrials.gov.